1. Home
  2. NNY vs CRDF Comparison

NNY vs CRDF Comparison

Compare NNY & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NNY
  • CRDF
  • Stock Information
  • Founded
  • NNY 1987
  • CRDF 1999
  • Country
  • NNY United States
  • CRDF United States
  • Employees
  • NNY N/A
  • CRDF N/A
  • Industry
  • NNY Investment Managers
  • CRDF Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NNY Finance
  • CRDF Health Care
  • Exchange
  • NNY Nasdaq
  • CRDF Nasdaq
  • Market Cap
  • NNY 159.8M
  • CRDF 152.3M
  • IPO Year
  • NNY N/A
  • CRDF N/A
  • Fundamental
  • Price
  • NNY $8.39
  • CRDF $2.04
  • Analyst Decision
  • NNY
  • CRDF Strong Buy
  • Analyst Count
  • NNY 0
  • CRDF 4
  • Target Price
  • NNY N/A
  • CRDF $10.63
  • AVG Volume (30 Days)
  • NNY 50.9K
  • CRDF 721.3K
  • Earning Date
  • NNY 01-01-0001
  • CRDF 11-06-2025
  • Dividend Yield
  • NNY 4.04%
  • CRDF N/A
  • EPS Growth
  • NNY N/A
  • CRDF N/A
  • EPS
  • NNY N/A
  • CRDF N/A
  • Revenue
  • NNY N/A
  • CRDF $501,000.00
  • Revenue This Year
  • NNY N/A
  • CRDF N/A
  • Revenue Next Year
  • NNY N/A
  • CRDF N/A
  • P/E Ratio
  • NNY N/A
  • CRDF N/A
  • Revenue Growth
  • NNY N/A
  • CRDF N/A
  • 52 Week Low
  • NNY $7.58
  • CRDF $1.90
  • 52 Week High
  • NNY $8.87
  • CRDF $5.64
  • Technical
  • Relative Strength Index (RSI)
  • NNY 50.12
  • CRDF 37.87
  • Support Level
  • NNY $8.40
  • CRDF $1.99
  • Resistance Level
  • NNY $8.58
  • CRDF $2.33
  • Average True Range (ATR)
  • NNY 0.13
  • CRDF 0.11
  • MACD
  • NNY -0.01
  • CRDF -0.03
  • Stochastic Oscillator
  • NNY 28.29
  • CRDF 12.16

About NNY Nuveen New York Municipal Value Fund

Nuveen New York Municipal Value Fund Inc. is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Share on Social Networks: